Alkermes plc
| Company type | Public |
|---|---|
| Industry | Biotechnology |
| Founded | 1987 |
| Founder | Michael Wall |
| Headquarters | , |
Key people | Richard Pops (CEO) |
| Revenue | Increase US$1.1 billion (2022)[2] |
| Decrease US$-20.5 million | |
| Decrease US$-158 million (2022) | |
| Total assets | Increase US$1.9 billion |
| Total equity | Increase US$1 billion |
Number of employees | 2,100 |
| Website | www.alkermes.com |
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall.[3] In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc.[4] The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.[1]
Products
[edit | edit source]Alkermes has four proprietary commercial drug products[5] approved for the treatment of schizophrenia, bipolar I disorder, alcohol dependence and opioid dependence. These include olanzapine and samidorphan (Lybalvi), an atypical antipsychotic and opioid modulator combination intended for the treatment of schizophrenia and bipolar I disorder; aripiprazole lauroxil (Aristada), a long-acting injectable for schizophrenia; and naltrexone for extended-release injectable suspension (Vivitrol) for alcohol and opioid dependence.
Other products utilizing Alkermes' proprietary technologies include: diroximel fumarate (Vumerity) for multiple sclerosis, risperidone (microspheres) long-acting injectable (Risperdal Consta) for schizophrenia and bipolar I disorder, paliperidone palmitate (Invega Sustenna, Invega Trinza and Invega Hafyerain in the U.S., Xeplion, Trevicta and Bynnali in Europe) for schizophrenia.[6][7]
In October 2023, Alkermes announced its first data related to its orexin 2 receptor (OXR2) agonist, alixorexton, previously known as ALKS 2680. Alixorexton is in development for the treatment of narcolepsy and idiopathic hypersomnia.[8]
In November 2023, Alkermes completed the planned separation of its oncology business into a new company, Mural Oncology, which plans to continue to work on the investigational interleukin-2 (IL-2) drug, nemvaleukin alfa.[9]
In May 2024, Alkermes completed the sale of its Athlone, Ireland facility to Novo Nordisk. [10]
In April 2025, Alkermes announced the initiation of a phase 2 study of alixorexton for the treatment of idiopathic hypersomnia. [11]
In July 2025, Alkermes announced positive topline results from Vibrance-1, a phase 2 study evaluating alixorexton for the treatment of narcolepsy type 1. [12]
In November 2025, Alkerms agreed to acquire sleep disorder drugmaker Avadel Pharmaceuticals for up to $2.37 billion, which includes $21 per share in cash plus $1.50 per share contingent on expanded approval of Lumryz by the end of 2028. This resulted after a bidding war between Alkermes and Danish pharmaceutical company Lundbeck. Alkermes had originally offered up to $2.1 billion, which inlcuded $18.50 per share plus the contingent $1.50. The deal is expected to close in the first quarter of 2026.[13]
References
[edit | edit source]- ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
External links
[edit | edit source]- Official website
- Business data for Alkermes plc:
Lua error in Module:Authority_control at line 153: attempt to index field 'wikibase' (a nil value).